Back to Search
Start Over
First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
- Source :
- Journal of Clinical Oncology. 36:1060-1061
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- PURPOSE: Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume. PATIENTS AND METHODS: In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m(2) for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis. RESULTS: At a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal therapy arm versus 47.2 months for ADT alone (hazard ratio [HR], 0.72; 95% CI, 0.59 to 0.89; P = .0018). For patients with high-volume disease (n = 513), the median OS was 51.2 months with chemohormonal therapy versus 34.4 months with ADT alone (HR, 0.63; 95% CI, 0.50 to 0.79; P < .001). For those with low-volume disease (n = 277), no OS benefit was observed (HR, 1.04; 95% CI, 0.70 to 1.55; P = .86). CONCLUSION: The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patients with low-volume disease, no OS benefit was discerned.
- Subjects :
- Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Standard of care
MEDLINE
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Text mining
Internal medicine
medicine
Humans
Survival analysis
business.industry
Androgen Antagonists
Prostatic Neoplasms
Standard of Care
ORIGINAL REPORTS
medicine.disease
Survival Analysis
Hormone-sensitive
First line treatment
030104 developmental biology
030220 oncology & carcinogenesis
business
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....82b06cb6a62a00879a8aec7aa9e34c72